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Background
Omalizumab is a monoclonal anti-IgE antibody approved
for the treatment of severe allergic asthma in patients
(pts) older than 6 years in Europe. Its efficacy in other
IgE-mediated diseases has been the target of several
recent studies.
Objective
Evaluate the safety and efficacy of omalizumab use in
allergic pts aged 6 to 18 years, followed in our Immu-
noallergology Department.
Methods
We retrospectively analyzed the clinical files of all pedia-
tric pts treated with omalizumab from December 2009 to
July 2013. The evaluated parameters included: adverse
reactions to omalizumab, clinical evolution, Asthma Con-
trol Test (ACT) and Severity Scoring of Atopic Dermatitis
(SCORAD) score evolution and medication decrease.
Statistical significance was defined by a p value in the
appropriate nonparametric test lower than 0.05.
Results
Ten pts (8M, 2F; mean age 12.9 [7-17] years) were pro-
posed for treatment with omalizumab due to severe
uncontrolled allergic disease: all pts had severe allergic
asthma, in 3 cases uncontrolled without oral corticoster-
oids (OCS). Furthermore, 5 children had severe eczema
(SCORAD>40), 1 had severe allergic conjunctivitis (AC),
1 was allergic to cow’s milk and experienced multiple
anaphylactic events in the course of milk specific oral tol-
erance induction (SOTI).This pediatric cohort has been
treated with omalizumab for an average of 12 [1-42]
months. No adverse reactions were attributable to its
administration. Average pretreatment ACT scores were
17 [15-19] and improved significantly (p<0.01) after
16 weeks of treatment to 23 [20-24]. In eczema pts,
SCORAD also improved significantly (p<0.01) after
16 weeks from 62 [34-90] to 24 [13-35]. All children dis-
continued OCS: After 2 months in the asthmatics and 3
months in the child with AC. One child with eczema
discontinued cyclosporine and one child reduced his
daily dose of azathioprine after 1 month. Due to con-
trolled disease, 2 pts were able to initiate specific immu-
notherapy. A successful cow’s milk SOTI (final daily
maintenance dose of 120ml) was possible after 3 adminis-
trations of omalizumab.
Conclusions
In this pediatric cohort, omalizumab was safe and effec-
tive not only in the control of asthma but also of other
uncontrolled allergic diseases. Furthermore, it allowed
for disease-altering immunotherapies to be initiated.
Additional studies are warranted for the use of omalizu-
mab in non-asthmatic allergic children, however its role
seems promising.
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